Overview of Diclofenac Tablets

Property	Description
Active Ingredient	Diclofenac potassium
Form	Oral, immediate-release tablet
Pharmacological Class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
General Purpose	Pain, fever, and inflammation relief
Origin	Synthetic, Phenylacetic acid derivative

What Type of Medicine is Diclofenac Tablets?

Diclofenac Tablets are a powerful synthetic medicine classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its core purpose is to provide relief from discomfort by addressing symptoms that arise from inflammation, including pain and fever, making it a highly effective analgesic, anti-inflammatory, and antipyretic agent. This class of drug is used to decrease swelling and fever. This means the medication provides general relief by reducing the physical symptoms associated with the body's inflammatory response. This class of drugs is utilized in managing acute, self-limiting discomfort.

Composition and Form: Diclofenac Potassium as an Oral Tablet

The active ingredient in this medication is Diclofenac potassium, which is the potassium salt of Diclofenac. The tablets are manufactured as an immediate-release solid dosage form, incorporating solid pharmaceutical excipients alongside the active substance. The potassium salt is absorbed more rapidly than the sodium salt of the same drug. This swift absorption means the medication is specifically formulated to offer relatively fast relief, a key differentiating factor often utilized when addressing conditions like acute muscular discomfort. Diclofenac belongs specifically to the phenylacetic acid derivative chemical group, confirming its structural differences from other common NSAIDs.

What is the General Therapeutic Purpose of this NSAID?

The general therapeutic purpose of this medication is to achieve a systemic anti-inflammatory, analgesic, and antipyretic effect by interfering with the body's natural pain and inflammation responses. It works by acting as a cyclooxygenase inhibitor, effectively limiting the production of prostaglandins, which are chemical messengers responsible for driving swelling and pain signals. This fundamental physiological action provides the basis for its general role in relieving acute discomfort, such as the temporary pain and inflammation following minor physical injury, and reducing elevated body temperature associated with inflammatory processes. The systemic, non-opioid nature of its effect makes it a first-line approach for many acute inflammatory states.

Regulatory References

What side effects are possible with Diclofenac Tablets?

Diclofenac Tablets: Possible Side Effects and Safety Information

Regulatory documentation structures the safety profile of Diclofenac Tablets, an NSAID, based on officially classified adverse reactions and systemic safety concerns. Adverse effects are grouped by their impact on major System-Organ Classes (SOC), including the Gastrointestinal, Cardiovascular, Renal, Hepatic, and Nervous systems.

Frequency and Common Reactions

Adverse reactions are classified by frequency in official labels. Common reactions often involve mild discomfort, such as headache, dizziness, nausea, diarrhea, dyspepsia, and elevated liver enzyme levels (transaminases). Reactions classified as Rare or Very Rare include serious events such as anaphylactic reactions, severe skin eruptions, and acute liver or kidney failure.

Serious Adverse Reactions and Constraints

The most serious risks documented in regulatory labeling are related to serious cardiovascular thrombotic events (e.g., myocardial infarction, stroke) and serious gastrointestinal toxicity (e.g., bleeding, ulceration, perforation), which can be fatal. The risk of these events is noted to increase with the duration of use and may be present early in treatment. The medication is formally contraindicated in the setting of coronary artery bypass graft (CABG) surgery and in patients with established congestive heart failure (NYHA Class II-IV) or ischemic heart disease.

Population-Specific Safety Notes

Official safety profiles include notes for specific patient groups. Older adults are documented to have a greater risk for serious gastrointestinal adverse events. Similarly, patients with pre-existing cardiovascular disease are noted to have a higher risk of serious thrombotic events, which structures the caution advised for use in these populations.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents state that immediate medical attention is required for any suspected overdose of Diclofenac Tablets.

Documented Overdose Manifestations

Symptoms documented in official labeling primarily involve the gastrointestinal (GI) and central nervous systems (CNS). GI effects include nausea, vomiting, stomach pain, and internal bleeding. CNS manifestations may present as dizziness, drowsiness, confusion, headache, and tinnitus, escalating to potential seizures or coma in severe cases.

Severe and Life-Threatening Outcomes

Severe toxicity can lead to acute renal failure, liver necrosis or failure, and life-threatening gastrointestinal perforation. These documented risks underscore the necessity for urgent emergency intervention following a large ingestion.

Emergency Actions and Management

Regulators mandate that emergency services or Poison Control must be contacted immediately. It is officially noted that no specific antidote is known for acute Diclofenac toxicity. Consequently, treatment is limited to symptomatic and supportive measures, including the use of activated charcoal, gastric lavage, and continuous monitoring of vital signs in a hospital setting.

Population-Specific Considerations

The official prescribing information notes that the elderly are at a higher risk for severe gastrointestinal complications. Patients with pre-existing renal or hepatic impairment, dehydration, or heart failure are cited as having an increased risk for acute kidney injury in the event of an overdose.

Therapeutic Uses of Diclofenac Tablets

What Diclofenac Tablets treats: main uses and benefits

The primary role of this medication is to provide symptomatic relief across various clinical contexts where symptoms related to physical discomfort and inflammatory states create a significant burden. It is used in situations involving symptomatic discomfort and systemic imbalance, commonly helping with symptoms associated with chronic arthritis, painful menstrual periods, and acute migraine attacks.

This medicine is applied in conditions characterized by periods of heightened symptoms, including rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, and episodic manifestations like severe menstrual cramps and the intensity of acute migraine attacks. The medication helps address symptom clusters that interfere with daily functioning, such as persistent joint pain, swelling, and debilitating stiffness.

The support provided is relevant during these phases, and the medication provides support that helps ease the overall symptom burden during these periods of heightened symptoms. This supports general well-being and assists with maintaining functional stability during symptomatic periods, particularly for patients managing long-term inflammatory processes.

Symptom Focus

The medicine is commonly used to help with three main symptomatic axes: reducing pain, easing inflammation (swelling, stiffness), and lowering elevated body temperature (fever).

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Diclofenac Tablets?

This medication is only for patients who do not have specific pre-existing conditions or risk factors, as defined by official regulatory documents. Use is restricted to the lowest effective dose for the shortest possible duration to mitigate serious risks.

Populations Who Must Not Use Diclofenac (Contraindications)

Classification	Exclusion Criteria
Allergy/Hypersensitivity	Known allergy to diclofenac or a history of asthma, urticaria, or other allergic reactions after taking aspirin or any other NSAID.
Surgery/Cardiac	Treatment of peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.
Pregnancy	Use at or after 30 weeks of gestation (late pregnancy).

Populations Requiring Caution or Avoidance

Use should generally be avoided or requires specific consideration in the following groups:

Patients with established cardiovascular disease (e.g., congestive heart failure [NYHA class II-IV], ischemic heart disease, peripheral arterial disease, cerebrovascular disease).
Individuals with a history of gastrointestinal bleeding or peptic ulcer disease.
Patients with advanced renal disease or severe heart failure; use only if the benefits are judged to outweigh the risks of worsening these conditions.
Safety and effectiveness are not established for use in pediatric patients.

Note: Older adults are at a greater risk for serious adverse events (gastrointestinal and cardiovascular) and should be monitored closely.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Diclofenac Tablets outlines several combinations with documented risks, classified by mechanism and resulting clinical outcome.

Contraindicated and High-Risk Combinations

The co-administration of Diclofenac Tablets is contraindicated in patients with a history of asthma, hives (urticaria), or other allergic-type reactions following the ingestion of Aspirin or other NSAIDs due to the risk of cross-sensitivity. Concomitant use with other NSAIDs is otherwise not generally recommended due to the potential for increased gastrointestinal risk.

Interacting Agents	Official Documented Outcome
Anticoagulants (e.g., Warfarin), SSRIs/SNRIs, Oral Corticosteroids	Increased Bleeding Risk: Synergistic effect on the risk of serious gastrointestinal bleeding.
Methotrexate	Increased Toxicity: Diclofenac may increase the toxicity of methotrexate by reducing its renal clearance.
Lithium and Digoxin	Increased Exposure: NSAIDs can elevate plasma levels of these agents and reduce their renal clearance.

Interactions Affecting Cardiovascular and Renal Agents

Diclofenac Tablets may diminish the antihypertensive effect of several drug classes, including ACE Inhibitors, ARBs, and Beta-Blockers. When used with Diuretics (e.g., Furosemide), Diclofenac can reduce their natriuretic (water-loss) effect. In the elderly or volume-depleted patients, co-administration of Diclofenac with ACE inhibitors, ARBs, or Diuretics may result in the deterioration of renal function, a specific population-based caution noted in official labeling.

Metabolic and Substance Interactions

The medicine is primarily metabolized via the CYP2C9 enzyme. CYP2C9 inhibitors (such as Voriconazole) can increase the systemic exposure of diclofenac, while CYP2C9 inducers (such as Rifampin) may lead to reduced efficacy. Alcohol intake is a documented risk factor for gastrointestinal bleeding that is exacerbated when combined with NSAID use.

Mechanism of Action

Molecular Blockade of Inflammatory Mediators

The drug’s core mechanism is reversible competitive inhibition of the Cyclooxygenase (COX) enzymes, particularly COX-2. This molecular blockade halts the conversion of arachidonic acid into prostaglandins, such as Prostaglandin E2 (PGE2), which are key chemical messengers that mediate physiological responses including inflammation and nociception. The potassium salt formulation promotes rapid systemic absorption, a mechanistic factor ensuring the inhibitory effect initiates quickly at peripheral and central sites.

Modulation of Peripheral Pain Signaling

By limiting the synthesis of PGE2 at peripheral tissue sites, the drug prevents the chemical sensitization of nociceptors (pain-sensing neurons). This mechanism results in an elevated nociceptive threshold, concurrently modulating vascular permeability to restrict fluid extravasation into tissues (edema). The pathway modulation results in the modulation of the inflammatory cascade and the attenuation of afferent nociceptive signaling.

Central Thermoregulatory Pathway Influence

The mechanism extends to the central nervous system (CNS), where the suppression of PGE2 synthesis within the hypothalamus reverses the body's elevated thermoregulatory set-point. This central action facilitates the initiation of heat dissipation mechanisms, leading to the physiological adjustment of core temperature. The overall mechanism is constrained by its reversible nature, meaning its pathway-modulating effects are time-limited and dependent on the drug's sustained concentration at the enzyme binding site.

Dosage and Administration Information

Diclofenac Tablets are indicated for oral administration as an immediate-release formulation, typically in a 50 mg strength. The overarching principle governing its use is the administration of the lowest effective dose for the shortest duration required.

Standard Dosing Regimens

For chronic conditions such as osteoarthritis and rheumatoid arthritis, the usual regimen involves 50 mg taken in two to four divided doses per day. In acute scenarios, including primary dysmenorrhea or acute pain, a starting dose of 100 mg may be followed by subsequent 50 mg doses, generally aiming for a total daily intake that does not exceed 150 mg to 200 mg, depending on the indication.

Administration Conditions

To ensure proper use, the tablets must be swallowed whole with liquid; they are not intended to be chewed, crushed, or divided. The recommendation is to take the tablets preferably with or after food.

For certain patient populations, including older adults or those considered frail, treatment begins at the lowest available effective dose. Furthermore, it is specified that this immediate-release tablet is not interchangeable with other diclofenac forms, such as enteric-coated or extended-release products, due to differing absorption profiles. The duration of administration varies, with acute pain management aimed at short-term use and chronic conditions requiring scheduled, ongoing maintenance within the duration limits established by the core dosing principle.

Recent Clinical Evidence

Diclofenac Tablets: Recent Clinical Evidence

This section summarizes key research that explores the drug's actions and potential benefits. This information is descriptive and does not constitute clinical advice, interpretation, or a recommendation for treatment.

Core Efficacy Studies

Initial clinical trials evaluated whether diclofenac could help with acute symptom relief. These trials included a broad spectrum of participants with varying levels of disease severity.

Short-Term Relief: Trials examined the time-to-onset of action and initial symptom reduction over short periods. The results provided data on the drug’s effect in the immediate term.
Long-Term Management: A study focusing on long-term management examined whether there was a reduction in symptom recurrence over a sustained period. Findings indicated this was a potential outcome.
Stabilization Potential: These results add to the data pool regarding the drug’s potential to help stabilize chronic conditions. Studies have included a review of dosage adherence and its association with observed outcomes.

Combination Use and Pharmacokinetics

Research has evaluated its use both alone and in combination with other therapeutic approaches.

Pharmacodynamic Interactions: Study analyses evaluated whether combination therapy was associated with improved patient outcomes. Study reports detail the observed changes in disease markers.
Mechanism of Action: Diclofenac is believed to act by inhibiting specific enzymes in the inflammatory pathway. Research continues to explore the full range of its cellular effects.

Safety and Tolerability Profiles

Safety profiles examined the treatment's tolerability in various patient groups, including those with pre-existing conditions.

Adverse Events: The overall incidence of reported adverse events in clinical trials was noted. The trials documented the incidence of adverse events and identified the most common reports.
Subgroup Analysis: Research teams are further examining whether specific patient subgroups exhibit different safety outcomes compared to the general trial population.

Key Studies & References NICE Guideline: Osteoarthritis: care and management

Frequently Asked Questions (FAQ)

Common questions about Diclofenac Tablets (FAQ)

Q: What are Diclofenac Tablets used for besides arthritis?

A: Regulatory documents indicate that Diclofenac Tablets are approved for the treatment of acute and chronic pain related to inflammatory conditions. These uses typically include osteoarthritis and rheumatoid arthritis, as well as relief for acute scenarios like primary dysmenorrhea, which is painful menstrual periods.

Q: What is the difference between Diclofenac Tablets and the Diclofenac topical gel?

A: The official product information for the tablets describes them as providing a systemic effect, meaning the medicine is absorbed into the bloodstream and works throughout the body. In contrast, topical gel formulations are generally intended for more localized pain and inflammation relief applied directly to the skin surface.

Q: How quickly do Diclofenac Tablets typically start to provide relief?

A: Based on pharmacokinetics studies, measurable levels of the drug may be seen in the bloodstream relatively quickly, sometimes within 10 minutes of taking a dose. Peak plasma levels, which is when the drug is most concentrated in the bloodstream, are generally described as being achieved within 1 to 2 hours, depending on the specific use conditions.

Q: How long do the effects of Diclofenac Tablets usually last in the body?

A: The drug is eliminated from the body relatively quickly. Official data shows the terminal half-life of unchanged diclofenac in the plasma is around 1 to 2 hours. This elimination rate is a factor considered in the design of the drug's approved dosing schedule, which often involves taking the medicine in divided doses to help sustain its effect.

Q: Can Diclofenac Tablets cause high blood pressure or affect existing hypertension?

A: Yes, official safety information states that Diclofenac, like other Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), can be associated with the development of new onset hypertension (high blood pressure) or the worsening of existing high blood pressure. Regulatory documents state that blood pressure monitoring is typically advised during the initiation of treatment and throughout its use.

Q: Is it normal to experience fluid retention or swelling (edema) when taking the tablets?

A: Regulatory documents list that fluid retention and edema (swelling of the hands or feet) have been observed in some patients receiving NSAID treatment. Because swelling can be a factor, individuals with certain pre-existing conditions, such as reduced heart function, should be monitored.

Q: What symptoms are described as potential signs of liver health issues while using this medicine?

A: Official health authorities warn that patients should watch for signs of liver problems, which may include the yellowing of the skin or eyes (jaundice). If abnormal liver tests persist or worsen, or if these symptoms appear, official guidance may require discontinuation of the drug.

Q: Can Diclofenac Tablets cause tinnitus (ringing in the ears)?

A: Clinical data reported in official sources indicates that tinnitus, which is a ringing or buzzing sound in the ears, has been reported as a potential side effect. This is classified among the ear and labyrinth disorders.

Q: Does Diclofenac Tablets contain any opioid or narcotic ingredients?

A: No, according to its composition, Diclofenac is strictly a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is not chemically related to or classified as an opioid or narcotic drug.

Q: What is the information available about using Diclofenac Tablets while breastfeeding?

A: Regulatory sources generally consider Diclofenac acceptable during breastfeeding because only very low levels of the drug pass into breast milk. However, official regulatory documents emphasize the importance of medical consultation before the medication is used while nursing an infant.

Q: Can Diclofenac Tablets cause increased sensitivity to the sun?

A: Official information mentions that photosensitivity reactions (an increased sensitivity to sunlight) have been reported, although they are generally considered rare. This means that skin reactions can be triggered by light exposure while using the drug.

Q: Is it possible for Diclofenac Tablets to be used for migraine headaches?

A: Official labeling for a specific diclofenac potassium formulation does indicate its use for the acute treatment of migraine attacks with or without aura in adults. However, this may be dependent on the exact formulation prescribed, as not all forms are approved for this indication.

Q: Does Diclofenac Tablets affect fertility in women?

A: Official documents state that as a prostaglandin synthesis inhibitor, the medicine can temporarily impair female fertility by interfering with ovulation. Regulatory information indicates that cessation of the drug is often recommended for women who are trying to conceive.

Q: What does 'delayed-release' or 'enteric-coated' mean for Diclofenac Tablets?

A: The terms 'enteric-coated' or 'delayed-release' describe a tablet coating designed to resist dissolving in the stomach. This formulation allows the tablet to pass through the stomach and dissolve later in the small intestine, which delays the onset of drug absorption.

Q: What kind of monitoring or lab tests may be required for long-term use of Diclofenac Tablets?

A: For patients receiving prolonged treatment, official documents advise that monitoring of hepatic function (liver tests) is indicated as a precaution. Routine monitoring of kidney function may also be recommended, particularly for individuals with existing risk factors.

Q: How does the risk profile of Diclofenac Tablets compare generally to naproxen in official documents?

A: Regulatory warnings emphasize that the cardiovascular risks of diclofenac may increase with dose and duration of use. Supporting clinical data mentioned in official documents suggests Diclofenac may carry a higher cardiovascular risk profile compared to some other NSAIDs, such as naproxen.

Q: What should a patient generally expect when stopping treatment with Diclofenac Tablets?

A: Since the mechanism of action is temporary and reversible, the drug’s anti-inflammatory and pain-relieving effects will wear off as the drug is eliminated from the body. If rebound headaches occur after stopping regular use, they may be resolved by discontinuing the medication, as noted in some health authority information.

Q: Does the medicine contain ingredients like lactose, sugar, or gluten?

A: Official labeling for inactive ingredients shows that some diclofenac tablet formulations contain lactose monohydrate. For specific concerns, consulting the full list of inactive ingredients is how the presence of other common excipients like sugar or gluten is confirmed.

Q: What is the general information about Diclofenac Tablets and blood clotting?

A: Diclofenac is described as having an anti-platelet effect, meaning it reduces the ability of blood platelets to aggregate (clot). This mechanism is associated with the known risks of serious gastrointestinal bleeding and thrombotic events detailed in the official warnings.

Q: Do Diclofenac Tablets have a boxed warning, and what does this mean?

A: Yes, Diclofenac Tablets carry an FDA Boxed Warning (also known as a Black Box Warning). This is a serious safety alert required by the FDA to call attention to the drug’s potential for serious cardiovascular thrombotic events (like heart attack or stroke) and severe gastrointestinal toxicity (like bleeding or ulcers).

Q: Can Diclofenac Tablets cause changes in vision?

A: Official documents report that visual disturbances, such as blurred vision and other changes in vision, have been observed as adverse effects. Official documentation indicates that if this symptom occurs, patients are generally advised to discontinue the drug and consult with their prescribing healthcare professional.

How should Diclofenac Tablets be stored and disposed of?

How to Store and Dispose of Diclofenac Tablets?

Storage

To maintain effectiveness and safety, store diclofenac tablets at room temperature, away from excess heat and moisture. Keep the medication in its original, tightly closed container and ensure it is always kept out of the reach of children and pets. Avoid storing it in a bathroom medicine cabinet due to humidity.

Disposal

The most recommended method for disposing of unused or expired diclofenac is through a drug take-back program. These programs, often available at pharmacies or police departments, ensure safe and environmentally responsible disposal.

If a take-back program is unavailable, you can dispose of the tablets in your household trash by following these steps to prevent accidental ingestion:

Remove tablets from their original container and mix them with an unappealing substance, such as used coffee grounds, dirt, or cat litter.
Place the mixture in a sealed bag or container.
Throw the sealed container in the trash.
Scratch out all personal information on the prescription label before discarding the original container.

Diclofenac Tablets